Cite
Harding JJ, Telli M, Munster P, et al. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2021;27(18):4994-5003doi: 10.1158/1078-0432.CCR-21-1204.
Harding, J. J., Telli, M., Munster, P., Voss, M. H., Infante, J. R., DeMichele, A., Dunphy, M., Le, M. H., Molineaux, C., Orford, K., Parlati, F., Whiting, S. H., Bennett, M. K., Tannir, N. M., & Meric-Bernstam, F. (2021). A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(18), 4994-5003. https://doi.org/10.1158/1078-0432.CCR-21-1204
Harding, James J, et al. "A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,18 (2021): 4994-5003. doi: https://doi.org/10.1158/1078-0432.CCR-21-1204
Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, Dunphy M, Le MH, Molineaux C, Orford K, Parlati F, Whiting SH, Bennett MK, Tannir NM, Meric-Bernstam F. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2021 Sep 15;27(18):4994-5003. doi: 10.1158/1078-0432.CCR-21-1204. Epub 2021 Jul 20. PMID: 34285061.
Copy
Download .nbib